Embryonic Stem Cells Derived Neuron Transplantation Recovery in Models of Parkinsonism in Relation to Severity of the Disorder in Rats

Rejuvenation Research

Volumn 18, Issue 2, 2015, Pages 173-184

  Haobam, Reena ^a,b   Tripathy, Debasmita ^a   Kaidery, Navneet A ^a,c   Mohanakumar, Kochupurackal P ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^b MANIPUR UNIVERSITY   (India)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; AMPHETAMINE; APOMORPHINE; DOPAMINE; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; BRAIN TRANSPLANTATION; CELL DIFFERENTIATION; CELL LOSS; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; DENERVATION; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; ELECTROCHEMISTRY; EMBRYONIC STEM CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOREACTIVITY; MALE; MOUSE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT; STEM CELL TRANSPLANTATION; STEREOMETRY; STEREOTAXIC SURGERY; SUBSTANTIA NIGRA PARS COMPACTA; ANIMAL; ANIMAL BEHAVIOR; BASAL GANGLION; BRAIN; CELL CULTURE; CHEMICALLY INDUCED; COMPARATIVE STUDY; CONVALESCENCE; DISEASE MODEL; DRUG EFFECTS; METABOLISM; MOTOR ACTIVITY; NERVE REGENERATION; NEURAL STEM CELL; PARKINSONIAN DISORDERS; PATHOLOGY; PATHOPHYSIOLOGY; PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; SPRAGUE DAWLEY RAT; TIME FACTOR; TRANSPLANTATION;

ANIMALIA; MURINAE; PARKINSONIA; RATTUS;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; BASAL GANGLIA; BEHAVIOR, ANIMAL; BRAIN; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOPAMINE; EMBRYONIC STEM CELLS; MALE; MICE; MOTOR ACTIVITY; NERVE REGENERATION; NEURAL STEM CELLS; OXIDOPAMINE; PARKINSONIAN DISORDERS; PARS COMPACTA; RATS, SPRAGUE-DAWLEY; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 84928479112     PISSN: 15491684     EISSN: 15578577     Source Type: Journal    
DOI: 10.1089/rej.2014.1626     Document Type: Article

References (49)

1. Bednar MM, Perry A. Neurorestoration therapeutics for neurodegenerative and psychiatric disease. Neurol Res 2012;34:29-42.
2. Politis M, Lindvall O. Clinical application of stem cell therapy in Parkinson's disease. BMC Med 2012;10:1.
3. Lindvall O, Kokaia Z. Prospects of stem cell therapy for replacing dopamine neurons in Parkinson's disease. Trends Pharmacol Sci 2009;30:260-267.
4. Arenas E. Towards stem cell replacement therapies for Parkinson's disease. Biochem Biophys Res Commun 2010;396:152-156.
5. Freed CR, Breeze RE, Rosenberg NL, Schneck SA, Wells TH, Barrett JN, Grafton ST, Huang SC, Eidelberg D, Rottenberg DA. Transplantation of human fetal dopamine cells for Parkinson's disease. Results at 1 year. Arch Neurol 1990;47:505-512.
6. Lane EL, Winkler C. L-DOPA- and graft-induced dyskinesia following transplantation. Prog Brain Res 2012;200:143-168.
7. Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, Shannon KM, Nauert GM, Perl DP, Godbold J, Freeman TB. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003;54:403-414.
8. Winkler C, Kirik D, Bjorklund A. Cell transplantation in Parkinson's disease: How can we make it work? Trends Neurosci 2005;28:86-92.
9. Venkataramana NK, Pal R, Rao SA, Naik AL, Jan M, Nair R, Sanjeev CC, Kamble RB, Murthy DP, Chaitanya K. Bilateral transplantation of allogenic adult human bone marrow-derived mesenchymal stem cells into the sub-ventricular zone of Parkinson's disease: A pilot clinical study. Stem Cells Int 2012;2012:931902.
10. Scatton B, Javoy-Agid F, Rouquier L, Dubois B, Agid Y. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 1983;275:321-328.
11. Ma Y, Tang C, Chaly T, Greene P, Breeze R, Fahn S, Freed C, Dhawan V, Eidelberg D. Dopamine cell implantation in Parkinson's disease: Long-term clinical and (18) F-FDOPA PET outcomes. J Nucl Med 2010;51:7-15.
12. García J, Carlsson T, Döbrössy M, Nikkhah G, Winkler C. Impact of dopamine versus serotonin cell transplantation for the development of graft-induced dyskinesia in a rat Parkinson model. Brain Res 2012;1470:119-129.
13. Bartlett LE, Sadi D, Lewington M, Mendez I. Functional improvement with low-dose dopaminergic grafts in hemiparkinsonian rats. Neurosurgery 2004;55:405-412.
14. Lang AE, Lozano AM. Parkinson's disease. First of two parts. N Engl J Med 1998;339:1044-1053.
15. Martínez-Martín P1, Gil-Nagel A, Gracia LM, Gómez JB, Martínez-Sarrié s J, Bermejo F. Unified Parkinson's Disease Rating Scale characteristics and structure. The cooperative multicentric group. Mov Disord 1994;9:76-83.
16. Przedborski S, Levivier M, Jiang H, Ferreira M, Jackson-Lewis V, Donaldson D, Togasaki DM. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 1995;67:631-647.
17. Banerjee R, Sreetama S, Saravanan KS, Dey SN, Mohanakumar KP. Apoptotic mode of cell death in substantia nigra following intranigral infusion of the parkinsonian neurotoxin, MPP + in Sprague-Dawley rats: Cellular, molecular and ultrastructural evidences. Neurochem Res 2007;32:1238-1247.
18. Saravanan KS, Sindhu KM, Mohanakumar KP. Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease. Brain Res 2005;1049:147-155.
19. Haobam R, Sindhu KM, Chandra G, Mohanakumar KP. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: A comparative study in two mouse strains. Behav Brain Res 2005;163:159-167.
20. Naskar A, Manivasagam T, Chakraborty J, Singh R, Thomas B, Dhanasekaran M, Mohanakumar KP. Melatonin synergizes with low doses of L-DOPA to improve dendritic spine density in the mouse striatum in experimental Parkinsonism. J Pineal Res 2013;55:304-312.
21. Kirik D, Rosenblad C, Björklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol 1998;152:259-277.
22. Kemmerer ES, Desmond TJ, Albin RL, Kilbourn MR, Frey KA. Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: Comparison of L-DOPA and pramipexole. Exp Neurol 2003;183:81-86.
23. Iancu R, Mohapel P, Brundin P, Paul G. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. Behav Brain Res 2005;162:1-10.
24. + or rotenone display differential sensitivity to amphetamine and apomorphine. Pharmacol Biochem Behav 2006;84:321-329,
25. Sawamoto K, Nakao N, Kakishita K, Ogawa Y, Toyama Y, Yamamoto A, Yamaguchi M, Mori K, Goldman SA, Itakura T, Okano H. Generation of dopaminergic neurons in the adult brain from mesencephalic precursor cells labeled with a nestin-GFP transgene. J Neurosci 2001;21:3895-3903.
26. Kim JH, Auerbach JM, Rodríguez-Gómez JA, Velasco I, Gavin D, Lumelsky N, Lee SH, Nguyen J, Sánchez-Pernaute R, Bankiewicz K, McKay R. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature 2002;418:50-56.
27. Senthilkumar KS, Saravanan KS, Chandra G, Sindhu KM, Jayakrishnan A, Mohanakumar KP. Unilateral implantation of dopamine loaded biodegradable hydrogel in the striatum attenuates motor abnormalities in the 6-hydroxydopamine model of hemiparkinsonism. Behav Brain Res 2007;184:11-18.
28. Carvalho MM, Campos FL, Coimbra B, Pêgo JM, Rodrigues C, Lima R, Rodrigues AJ, Sousa N, Salgado AJ. Behavioral characterization of the 6-hydroxidopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits. Mol Neurodegener 2013;8:14.
29. Grealish S, Mattsson B, Draxler P, Björklund A. Characterization of behavioural and neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model of Parkinson's disease. Eur J Neurosci 2010;31:2266-2278.
30. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. Academic Press, New York, 1982.
31. Ungerstedt U, Arbuthnott GW. Quantitative recording of rotational behavior in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res 1970;24:485-493.
32. Tripathy D, Haobam R, Nair R, Mohanakumar KP. Engraftment of mouse embryonic stem cells differentiated by default leads to neuroprotection, behaviour revival and astrogliosis in parkinsonian rats. PLoS One 2013;8:e72501.
33. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigrostriatal dopamine system. Acta Physiol Scand Suppl 1971;367:69-93.
34. Chakraborty J, Singh R, Dutta D, Naskar A, Rajamma U, Mohanakumar KP. Quercetin improves behavioral deficiencies, restores astrocytes and microglia, and reduces serotonin metabolism in 3-nitropropionic acid-induced rat model of Huntington's disease. CNS Neurosci Ther 2014;20:10-19.
35. Muralikrishnan D, Mohanakumar KP. Neuroprotection by bromocriptine against 1- methyl-4-phenyl-1,2,3,6-tetra-hydropyridine-induced neurotoxicity in mice. FASEB J 1998;12:905-912.
36. McRae A, Hjorth S, Dahlström A, Dillon L, Mason D, Tice T. Dopamine fiber growth induction by implantation of synthetic dopamine-containing microspheres in rats with experimental hemi-parkinsonism. Mol Chem Neuropathol 1992;16:123-141.
37. Tripathy D, Verma P, Nthenge-Ngumbau DN, Banerjee M, Mohanakumar KP. Regenerative therapy in experimental parkinsonism: Mixed population of differentiated mouse embryonic stem cells, rather than magnetically sorted and enriched dopaminergic cells provide neuroprotection. CNS Neurosci Ther 2014;20:717-727.
38. Robichon R, Jaafar A, Terqui M, Brachet P, Peschanski M. Pig xenografts to the immunocompetent rat brain: Survival rates using distinct neurotoxic lesions in the nigrostriatal pathway and two rat strains. Exp Neurol 2005;194:333-340.
39. Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, Dillon S, Winfield H, Culver S, Trojanowski JQ, Eidelberg D, Fahn S. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001;344:710-719.
40. Nikkah G, Rosenthal C, Falkenstein G, Roedter A, Papazoglou A, Brandis A. Microtransplantation of dopaminergic cell suspensions: Further characterization and optimization of grafting parameters. Cell Transplant 2009;18:119-133.
41. Kirik D, Winkler C, Björklund A. Growth and functional efficacy of intrastriatal nigral transplants depend on the extent of nigrostriatal degeneration. J Neurosci 2001;21:2889-2896.
42. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nature Med 2008;14:504-506.
43. Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, Rehncrona S, Björklund A, Widner H, Revesz T, Lindvall O, Brundin P. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 2008;14:501-503.
44. Thornton E, Vink R. Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson's disease. PLoS One 2012;7:e34138.
45. Watmuff B, Pouton CW, Haynes JM. In vitro maturation of dopaminergic neurons derived from mouse embryonic stem cells: Implications for transplantation. PLoS One 2012;7:e31999.
46. Gaillard A, Decressac M, Frappé I, Fernagut PO, Prestoz L, Besnard S, Jaber M. Anatomical and functional reconstruction of the nigrostriatal pathway by intranigral transplants. Neurobiol Dis 2009;35:477-488.
47. Thompson LH, Grealish S, Kirik D, Björklund A. Reconstruction of the nigrostriatal dopamine pathway in the adult mouse brain. Eur J Neurosci 2009;30:625-638.
48. Carman LS, Gage FH, Shults CW. Partial lesion of the substantia nigra: Relation between extent of lesion and rotational behavior. Brain Res 1991;553:275-283.
49. Politis M, Wu K, Loane C, Kiferle L, Molloy S, Brooks DJ, Piccini P. Staging of serotonergic dysfunction in Parkinson's disease: An in vivo 11C-DASB PET study. Neurobiol Dis 2010;40:216-221.